Talha Badar, Associate Professor of Medicine at Mayo Clinic, shared on X:
“Pleasure to speak at the 35th Annual Mayo Clinic Hematologic Malignancies Review on ‘Frontline Therapy in Transition: Integrating Immunotherapy Across Ph-negative and Ph-positive ALL.’
The field continues to evolve rapidly from chemotherapy-intensive approaches to response-adapted, MRD-guided, immunotherapy-based strategies. Exciting discussions on optimizing sequencing, transplant decisions, and the future of cellular therapies.
A special thank you to Dr. Rami Manochakian for organizing another outstanding educational meeting that brought together experts from across hematologic malignancies.”
Other articles featuring Talha Badar on OncoDaily.
